Yu no bɔt di kansa we nɔ kin bɔku we dɛn kɔl Sarcomatoid Carcinoma? Lɛ wi tɔk ditayli!

Kansa de mek wi ɔl fred smɔl, nɔto so? Bɔt nɔto ɔl di kansa dɛn na di sem. Tide wi go tɔk bɔt wan kayn kansa we nɔ kin bɔku ɛn we kin kɔmpleks. Dɛn kɔl am Sarcomotoid Carcinoma. Di nem kin tan lɛk se i strenj to yu, bɔt lɛ wi tray fɔ ɛksplen am simpul wan. Dɔktɔ dɛn kɔl dis wan kayn kansa we de gro kwik kwik wan ɛn we kin mek pɔsin vɛks .

Wetin na Sarkomatoid Kansa?

Fɔ tɔk am simpul wan, Sarcommatoid Carcinoma na wan kɔmbaynshɔn fɔ tu kayn kansa. Dat min se, i gɛt di kwaliti dɛn we de sho se pɔsin gɛt kansa ɛn sarkoma. Naw lɛ wi si wetin na kansa ɛn sarkoma.

• Kansa: Dis na di kayn kansa wae kin pasmak. I kin bigin na di tisu dɛm we de kɔba di say we wi ɔgan ɔ skin de. wi kכl dεn tisu dεm ya εpitel tisu biכs dεn mek dεm wit εpitεlial sεl dεm.
• Sarkoma: Dis nɔ kin bɔku lɛk kansa. sarkoma de stat na ples dεm lεk bon, kכnektiv tisu (e.g., katilej, tεndon), εn sכft tisu (e.g., mכsul, fεt, nεv dεm). dεn mek dεm wit wan kayn sεl we dεn kכl mεsenchymal sεl dεm.

So, insay di kes fɔ sarkomatoid kansa, wan tumbu we gɛt sɛl ɛn tisu dɛn we gɛt fɔ du wit ɔl tu di kansa ɛn sarkoma de fɔm. dis tכmכro dεm de gro kwik kwik wan εn kin spre (mεtastasayz) to difrεn pat dεm na di bכdi. We dis de skata, di hεlty tisu dεm na di bכdi de pwεl.

Usay na di bɔdi dis kin apin mɔs?

We yu yɛri di nem sarcommatoid carcinoma, yu go mɔs gɛt sɔntin fɔ du wit yu lɔng dɛn . Bɔt dis kayn kansa, we gɛt di kayn kansa ɛn sarkoma, kin apin bak na ɔda pat dɛn na di bɔdi. Fɔ ɛgzampul:

• Kanda
• Bon
• Mɔt
• Tayrɔyd gland we dɛn kɔl
• Brest dɛn
• Bɛlɛ
• Smɔl intestin
• Liva
• Pankrias we de na di bɔdi
• Uterus we de na di bɛlɛ
• Prɔstat
• Blada we de na di bɔdi
• Kidni dɛn
• di spεs we de na di midul pan di chεst (dεn kכl dis ``Mediastinum''. tin dεm lεk di at, di trakya, εn di taymus gland de ya)

Dɛn se sarcomatoid carcinoma, we kin bigin na di lכng, kin spre kwik kwik wan. dis we ya, i kin spre to difrεn ples dεm wan tεm, lεk di adrenal gland dεm, di bren, di bon dεm, di liva, di kidni dεm, di pεritoneum, di pankrias, di skin, εn di at.

Yu tink se difrɛn kayn dis de bak?

Yes, di Wol Wɛlbɔdi Ɔganayzeshɔn (WHO) bin put sarkomatoid kansa insay fayv men kayn dɛn insay 2015. Dɛn kɔl ɛni wan pan dɛn kayn ya "poorly differentiated non-small cell lung carcinoma." "Poorly differentiated" min se di sεl dεm dεn so abnכmal difrεns dat i at fכ tכk εgzakli us tכp dεn bi. Nɔn-smɔl sɛl lɔng kansa na wan kɔmɔn kayn lɔng kansa we de gro ɛn skata kwik kwik wan.

Dɛn fayv kayn dɛn ya na:

• Pleomorphic carcinomas: Dɛn wan ya gɛt mɔs pan di kansa ficha dɛm. כltu, at le 10% pan dεm kin gεt sarkoma fכm dεm. Dis na di kayn sarkomatoid kansa we kin bɔku pas ɔl.
• Spindle-cell carcinoma: Dis kayn kansa gɛt in nem frɔm di we aw in sɛl dɛn de luk ɔnda maykroskɔp. Dɛn lɔng, dɛn tan, ɛn dɛn tan lɛk di spindl dɛn we de na wil we de spin.
• Jaynt sεl kansa: Dis gεt big sεl dεm we dεn arenj insay wan patεn we lεk sarkoma. dis kin fכm na di כp pat na di lכng.
• Carcinosarcoma: Dis inklud tisu frɔm sɔm kayn kansa, lɛk adenocarcinoma ɛn squamous cell carcinoma. I inklud bak di sarkoma tisu we nɔrmal, we nɔ de divɛlɔp fayn.
• Pulmonary blastoma: dis na wan kayn adenocarcinoma we lεk di lכng tisu fכ pikin. yu kin si di mεsenchymal sεl dεm (lεk sarkoma) bak.

Udat dɛn kin gɛt dis sik mɔ?

Sarkomatoid Carcinoma na di wan we kin apin mɔ pan man dɛn . I kin mɔna pipul dɛn we de yuz tabak naw ɔ we dɔn yuz am trade . Di avrej ej fɔ no di sik na lɛk 65 ia.

Aw kɔmɔn tin dis?

Dis na wan kayn kansa we nɔ kin bɔku . Sarkomatoid Carcinoma de mek wan rili sכm pasεnshכn pan כl di lכng kεnsar dεm, bitwin 0.1% εn 0.4%.

Wetin na di sayn dɛm fɔ dis?

De sayn dɛm wae yu kin gɛt kin dipen pan usai de kansa dɔn skata na yu bɔdi. If yu gɛt sarcommatoid carcinoma na di lɔng, yu kin gɛt sɔm sayn dɛm lɛk:

• Kɔf (we de kɔntinyu fɔ kɔf) .
• I nɔ izi fɔ blo (dyspnea) .
• Chɛst de pen
• Bliding wit mucus
• We yu de lɔs yu wet witout ɛni rizin

Wetin mek sɔntin lɛk dis kin apin?

Dɔktɔ dɛn biliv se wan men tin we kin mek pɔsin gɛt sarkomatoid kansa na wan prɔses we dɛn kɔl "Epithelial-Mesenchymal Transition (EMT)." fכ simpul wan, dis na we di kεnsar εpitεlial sεl dεm na nכn sכm sכl lכng kansa de chenj, εn sכm pan dεm de tכn to mεsenchymal sεl dεm. Di kansa sɛl dɛm we dɔn chenj dis we ya kin skata kwik kwik wan ɔlsay na di bɔdi.

dis chenj dεm we de apin na di sεl dεm εn di fכ gro kwik kwik wan kin kכmכt wit di jεnεtik mכtεshכn dεm na di sεl dεm . Yu no se wi jin na di instrɔkshɔn dɛn we de tɛl di sɛl dɛn aw fɔ biev. Jɛnɛtik muteshon na chenj ɔ mistek pan dɛn instrɔkshɔn dɛn de. Sayɛnsman dɛn dɔn fɛn bɔku tin dɛn we kin chenj na di jɛnɛtiks we gɛt fɔ du wit sarkomatoid kansa.

Wetin na de risk factor wae kin afekt dis?

Risk factor na sɔmtin wae de mek pɔrsin gɛt mɔr chans fɔ gɛt sik. Insay di kes fɔ sarkomatoid kansa, fɔ smok na di men tin ɛn di tin we pipul dɛn sabi pas ɔl. I fayn fɔ no se bitwin 80% ɛn 90% pan di pipul dɛn we gɛt dis lɔng kansa na pipul dɛn we de smok naw ɔ we dɔn de smok trade.

Nɔ fɔgɛt se if yu lɛf fɔ smok, dat kin mek yu nɔ gɛt bɔku sik dɛn na yu lɔng, lɛk kansa lɛk dis wan.

Aw dɔktɔ kin no dis?

Yu dɔktɔ go fɔs chɛk yu ɛn if nid de, i go du sɔm tin dɛn fɔ tek pikchɔ. Bɔt fɔ mek shɔ se dis na sarkomatoid kansa, dɛn nid fɔ tek bayɔpsi fɔ chɛk di kansa sɛl dɛn.

• Imajin: Di dɔktɔ kin du CT skan fɔ si usay di kansa de. fכ mek yu si di insay pat pan di bכdi klia wan, dεn kin du CT/PET skan כ F-fluorodeoxyglucose (FDG)-PET skan. CT/PET skan de kam togεda tu tεst dεm (CT εn PET) di sem tεm. Fluorodeoxyglucose na kεmikכl we dεn kin injεkt insay di bכdi we dεn de du PET skan. I kin gɛda rawnd di kansa sɛl dɛn, we kin mek pɔsin si dɛn mɔ we dɛn de skan.

• Histopathology: Histopathology na di maykroskɔpik egzamin fɔ wan sɛmpul fɔ di kansa tisu we dɛn tek frɔm bayɔpsi. di we aw di sεl dεm de sho kin εp di dכkta fכ no if na sarkomatoid kansa εn if na so, us sכbtayp i bi (e.g., pleomorphic carcinoma, spindle cell carcinoma).

• Imyunohistokɛmistri: .dis tεst de luk fכ sכbstans dεm we dεn kכl antijen dεm we de sho sכm kayn sεl dεm. sכm antijen dεm kin no se wan sεl abnכmal כ malign.

Aw dɛn kin trit am?

Di tritmɛnt we go wok pas ɔl fɔ dis kansa na fɔ ɔpreshɔn fɔ pul di wan ol tumbu. Kimotɛrapi kin ɛp fɔ kil ɛni kansa sɛl we lɛf afta dɛn dɔn du di ɔpreshɔn. Bɔt bɔku tɛm, di kansa kin dɔn skata bay di tɛm we dɛn no se i gɛt am, so i nɔ go pɔsibul fɔ mek dɛn du ɔpreshɔn pan am. If prɔblɛm dɛn de lɛk pen, blɔd, ɔ i nɔ izi fɔ blo, dɛn kin gi am redyushɔn tɛrapi bak.

If na sarkomatoid kansa, klinik trial kin bi di bɛst tritmɛnt opshɔn. Klinik trial na stɔdi we de tɛst if nyu tritmɛnt dɛn sef ɛn if dɛn wok fayn. Naw, sayɛnsman dɛm de du risach bɔt tritmɛnt dɛm wae go ɛp fɔ mek yu liv wit dis kansa fɔ lɔng tɛm. Tu pan dɛn na:

• Targeted therapy: Dis involv fɔ target di patikyula kwaliti dɛm we de mek di kansa sɛl dɛn bɔku we dɛn nɔ ebul fɔ kɔntrol.
• Immunotherapy: Dis kin mek yu imyun sistɛm wok fayn, ɛn i kin ɛp am fɔ fɛn ɛn pwɛl di kansa sɛl dɛn.

Wetin wi go du fɔ ridyus di prɔblɛm?

If yu disayd nɔ fɔ yuz tabak, yu kin ridyus yu risk fɔ gɛt sarcommatoid carcinoma, ɛn bɔku ɔda kansa dɛn na yu lɔng. Dis na di impɔtant tin we yu go du.

Yu tink se dis kin mɛn kpatakpata?

Infakt, sarkomatoid kansa na wan kayn kansa we kin at fɔ mɛn ɔltogɛda. Bɔt as sayɛnsman dɛn de lan mɔ bɔt di sɛl dɛn we dɛn tumbu ya gɛt, lɛk we dɛn de chenj dɛn jɛnɛtiks, dɛn kin ebul fɔ mek nyu tritmɛnt dɛn we de tɔk bɔt dɛn. If dɛn no se yu gɛt dis sik, yu kin ebul fɔ tek pat pan klinik trial we de tɛst nyu tritmɛnt dɛn. Aks yu dɔktɔ bɔt dis.

Aw lɔŋ yu fɔ liv wit dis sik?

E tranga fɔ tɔk aw lɔng yu go liv na dis kayn tin, bɔt i impɔtant fɔ no. pan avrej, di midyan rεt we de liv na bכt 10 mכnt. di fayv ia sכvayv rεt na bכt 15%. Bɔt dɛn statystik ya nɔ de apin to ɔlman di sem we. Bɔku tin dɛn de we kin afɛkt yu sityueshɔn:

• Di patikyula kayn sɛl we de insay kansa.
• Wetin na di jin muteshon dɛm we dɔn apin?
• Aw lɔng i tek frɔm di biginin fɔ di sik te dɛn no bɔt di sik.
• Aw fa di kansa dɔn gro ɛn pwɛl di wɛlbɔdi tisu.
• Aw fa di kansa dɔn skata.
• If di dɔktɔ go ebul fɔ pul di kansa tɔŋ kpatakpata.

So, e fayn fɔ tɔk opin wan bɔt ɔl dis wit yu dɔktɔ fɔ mek yu ɔndastand yu sik gud gud wan.

Wetin na di impɔtant kwɛstyɔn dɛn we wi fɔ aks di dɔktɔ?

We yu kam fɔ no se yu gɛt sarkomatoid kansa, yu kin rili wɔri ɛn kɔnfyus bikɔs dɛn kansa ya difrɛn ɛn kɔmpleks. I impɔtant fɔ tɔk to yu dɔktɔ opin wan bɔt di tritmɛnt we yu go gɛt ɛn aw di sik go bi tumara bambay. Yu dɔktɔ kin ɛksplen to yu wetin fɔ ɛkspɛkt bay aw yu kansa sɛl dɛn tan ɛn usay di kansa de na yu bɔdi.

Na sɔm kwɛstyɔn dɛn we yu kin aks yu dɔktɔ:

• Yu tink se mi kansa dɔn skata?
• Aw mi kansa rili bad?
• Us kayn tritmɛnt yu kin advays?
• Us sayd ɛfɛkt dɛn fɔ ɛkspɛkt frɔm di tritmɛnt?
• Yu tink se i go fayn fɔ mek a gɛt sɛkɔn mɛdikal opinion?
• A fɔ wok wit spɛshal pipul dɛn we de kia fɔ di sik we dɛn kɔl palliativ kia?
• A fit fɔ tek pat pan klinik trial?

Yu dɔktɔ kin gi yu di infɔmeshɔn we yu nid, rifer yu to klinik trial if yu kwalifay, ɛn ɛp yu fɔ gɛt palliativ kia.

Tin dɛn we wi nid fɔ mɛmba

Okay, so, frɔm wetin wi dɔn tɔk bɔt Sarcomatoid Carcinoma, na di men tin dɛm fɔ mɛmba:

• Dis na wan kayn kansa wae nɔr kin bɔrku, wae kin agresiv wae kin prɛd kwik kwik wan.
• Dis de sho di ficha dɛm fɔ ɔl tu di kansa ɛn sarkoma.
• Smok na di men tin we kin mek pɔsin gɛt dis.
• Di sayn dɛm kin dipen pan usay di kansa de. Insay di lɔng, di sayn dɛm kin bi fɔ kɔf ɛn i nɔ kin izi fɔ blo.
• Dɛn nid spɛshal tɛst (bayɔpsi, imej) fɔ no if pɔsin gɛt di sik.
• Di tritmɛnt we dɛn kin pik kin kɔmpleks. Apat frɔm ɔpreshɔn, kemotɛrapi, ɛn redyushɔn tɛrapi, dɛn de tink bak bɔt nyu tritmɛnt dɛn (targeted therapies, immunotherapy).
• Pan ɔl we di chans fɔ mek i wɛl ɔltogɛda nɔ bɔku, nyu risach dɔn gi op.
• E fayn fɔ tɔk to yu dɔktɔ opin wan bɔt yu sik ɛn no ɔltin klia wan.

A op se dis infɔmeshɔn go ɛp yu. If yu gɛt ɛni ɔda kwɛstyɔn bɔt dis, duya nɔ fred fɔ go to dɔktɔ.

` Sarkomatoid kansa, kansa, lɔng kansa, smok, kansa simptom, kansa tritmɛnt, kansa